| Assessment Status | Rapid Review Complete |
| HTA ID | 21053 |
| Drug | Latanoprost/Timolol |
| Brand | Fixapost® |
| Indication | In adults (including the elderly) for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta‐blockers or prostaglandin analogues. |
| Assessment Process | |
| Rapid review commissioned | 16/11/2021 |
| Rapid review completed | 06/12/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Fixapost® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement April 2022.
